Heart attack: new approved treatment
Health Canada clears the use of Diovan to reduce mortality in people who have had a heart attack. Currently, one in three people die in the year following a first crisis. Diovan can now be used for purposes other than those for which it was designed. A drug can be bought with price around $214 for a supply of 30 tablets, you can also reduce your medical bills with using Diovan coupon which can save up to 80%.
Health Canada estimates that taking this drug, from Novartis, can reduce mortality in people who have had a heart attack. Originally, the drug was created as an angiotensin receptor antagonist. It is currently the most prescribed in the world for mild to moderate hypertension.
The VALIANT study, which enrolled more than 14,000 patients from 24 countries, showed that Diovan is well tolerated and offers additional benefits for individuals at high risk for cardiovascular complications.
Cardiologist Christian Constance of Hospital Maisonneuve-Rosemont estimates that one out of every three patients surviving a heart attack is at risk of dying within a year. According to it, the current standard treatment fails to reduce this significant risk because patients have problems with adherence. In addition, side effects are sometimes difficult to tolerate.
The VALIANT study results were published in the New England Journal of Medicine, and were presented at the November 2003 American Heart Association scientific meetings. High blood pressure affects about one in five Canadians. It increases the risk of heart attack, along with smoking, obesity, high cholesterol and diabetes. Not less than 70,000 Canadians will have a heart attack this year.
The Swiss group presented very convincing clinical results. The new product could offset the loss of Diovan’s patents.
Invent new treatments that significantly improve the management of patients with cardiovascular diseases, both medically and economically, it is possible. Novartis has just provided proof of this with the clinical results that the Swiss group presented this weekend in Barcelona at the Congress of the European Society of Cardiology. The new drug, dubbed LCZ696, tested on 8,400 heart failure patients, reduces the risk of cardiovascular death and the number of hospitalizations for heart failure by 20% compared to the current reference treatment (inhibitors of angiotensin converting enzyme).
Heart failure is characterized by the inability of the heart to provide sufficient blood flow, with symptoms of shortness of breath, fatigue and edema. It affects 5 to 6 million Americans and as many Europeans, and is today the leading cause of hospitalization in developed countries. “At a time when all countries are trying to control their health care costs, a drug that significantly reduces hospitalizations can help,” said David Epstein, director of Novartis’s Pharmacy Division.
Cardiovascular disease is an area where innovation is a real challenge: as these diseases are widespread, clinical trials must be performed on many patients, resulting in a high cost and a significant penalty in case of failure. Novartis is one of the few groups still pursuing active research in this area, including to compensate for the loss of patents of Diovan, which was its flagship antihypertensive drug. The LCZ696 is, moreover, only a combination of Diovan with a new class of molecules. The American BMS was less fortunate in 2002 when he tried to combine a Diovan type molecule with conventional treatment. The product had been recalibrated because of serious side effects. A rejection also experienced by Novartis, there is little, with Serelaxine, a potential product against acute heart failure whose results were found to be insufficiently conclusive.
Novartis plans to submit a marketing authorization dossier for the LCZ696 before the end of the year in the United States and early 2015 in Europe. The product could therefore be marketed as early as next year. Some analysts expect a price of $7 a day against $4 for current treatments that are generic.